



Third Party Governance of Industry- Sponsored Tobacco Product Research – A Public Workshop


March 20th 2013

Justine Williamson PhD, Head of Biosciences




Overview:

- BAT scientists today
- Expertise
- Transparency
- Research partners
- Governance & conduct
- Summary



Biosciences Department 2013



Expertise:

Historical areas of Expertise	Areas growing over past 5-10 yrs	New areas developing
Combustion Science	Biomarkers	Risk perception /understanding
Analytical Chemistry	Computational toxicology	Post Market Surveillance
Tobacco Biotechnology	<i>In vitro</i> models of disease	Biostatistics
Smoking Topography	Clinical studies	e-cigarette science
Dosimetry	Pharmacokinetics	Population modelling
Toxicology	Smokeless tobacco science	
Sensory Research	-omics	
	Quality of Life	

Transparency:

■ Publication in peer-reviewed journals

- ~100 publications since '08
- in 45 journals
- Referees for >40 journals



Toxicology in Vitro

Volume 27, Issue 1, February 2013, Pages 513–522



Review

In vitro models for assessing the potential cardiovascular disease risk associated with cigarette smoking

Open Access Article

Ian M. Fearon^{*}, Marianna D. Gaça^{*}, Brian K. Nordskog^{*}

^{*} British American Tobacco, Group R & D, Regents Park Road, Southampton SO15 8TL, UK

^{*} R.J. Reynolds Tobacco, Winston-Salem, NC 27102-1487, USA

<http://dx.doi.org/10.1016/j.tiv.2012.08.018>, How to Cite or Link Using DOI

Permissions & Reprints

Abstract

Atherosclerotic cardiovascular disease is a prevalent human disorder and a significant cause of human morbidity and mortality. A number of risk factors may predispose an individual to developing atherosclerosis, and of these factors, cigarette smoking is strongly associated with the development of cardiovascular disease. Current thinking suggests that exposure to toxicants found in cigarette smoke may be responsible



Chemistry Central
Journal

IMPACT
FACTOR
3.28

Search for

Home

Articles

Authors

Reviewers

About this journal

My Chemistry Central Journal

Top

Abstract

Background

Results

Discussion

Research article

Real-time assessment of cigarette smoke particle deposition *in vitro*

Jason Adamson, Sophie Hughes, David Azzopardi, John McAughey and Marianna D Gaça^{*}

Open Access

Nicotine & Tobacco Research, Volume 15, Number 1 (January 2013) 255–261

Original Investigation

Determination of Nicotine Absorption from Multiple Tobacco Products and Nicotine Gum

Helena Digard, B.Sc.,¹ Christopher Proctor, Ph.D.,¹ Anuradha Kulasekaran, M.B.B.S., M.D.,¹ Ulf Malmqvist, M.D., Ph.D.,² & Audrey Richter, Ph.D.¹

¹ Group R&D, British American Tobacco (Investments) Ltd., Southampton, United Kingdom

² Clinical Research and Trial Centre, Lund University Hospital, Lund, Sweden


Corresponding Author: Audrey Richter, Ph.D., Group R&D, British American Tobacco (Investments) Ltd, Regents Park Road, Southampton SO15 8TL, United Kingdom. Telephone: +44-2380-793181; Fax: +44-2380-793480; E-mail: audrey_richter@bat.com

Received November 16, 2011; accepted April 2, 2012

Abstract


Introduction: Snus is a smokeless tobacco product traditionally used in Scandinavia and available in pouched or loose forms. The objective of this study was to determine nicotine absorption for current pouched and loose snus products in comparison with a cigarette and an over-the-counter nicotine gum

form of tobacco has a history of use in Sweden that dates back several hundred years, although its composition and manufacturing processes have evolved over time. The main ingredients are finely ground tobacco, water, salt, humectants, and flavors. It is currently available in two distinct forms: a loose compacted tobacco or portions of tobacco sealed in small sachets termed “nouches.” The nouch weight of tobacco ranges from approx-



Transparency:

- bat-science.com
 - Launched in 2008
 - Overview of research programmes
 - Library: 200 BAT publications
: 240 BAT posters



Research & Development
at British American Tobacco

About R&D
Science
Smokeless
Careers
Library
Glossary

☒ Entire Site
☐ Library
Search

This website is written specifically for scientists with an interest in tobacco-related research or related disciplines. We hope it may also be of interest to members of the public health and regulatory communities.

As a scientist you will be aware that apart from references to journal publications, the material has not been subject to formal external peer review.

For non-scientists there is a summary of our research on our corporate website www.bat.com.

David O'Reilly PhD
Group Scientific Director

"I believe that tobacco harm reduction has the potential to be one of the biggest public health opportunities of this generation. Although the proportion of adults who smoke is likely to decline, population growth means that in 10-years time there will likely be as many or more smokers globally as there are today. We are working towards producing a range of lower-risk products for the millions of adults globally who will continue to consume tobacco and nicotine products. However, we recognise that the

IVTIP Annual Meeting 2013

The In Vitro Testing Industrial Platform, IVTIP, will be hosting their 2013 Spring Meeting at our Research & Development site in Southampton, UK. The meeting will be hosted in our new auditorium from May 14th-16th.

[Read more about this meeting](#)

Quantifying Cigarette Smoke Deposition in vitro

A novel technique developed by our scientists has made it possible to weigh the amount of smoke a person is likely exposed to when they take a puff of a cigarette. These measurements will enable the development of more relevant in vitro assays.

[View the full news release and publication](#)

MicroRNAs are promising biomarkers of smoking-related diseases

Because microRNAs play a vital role in regulating gene expression, in addition to their inherent stability, this makes them suitable biomarker candidates for the early detection of molecular and genetic changes associated with smoking-related diseases. A recent article from BAT reviews this emerging field.

Home | Accessibility | Site map | Links | Contact us | Conditions of use | Group websites

Research & Development
at British American Tobacco

About R&D
Science
Smokeless
Careers
Library
Glossary

☒ Entire Site
☐ Library

Publications
Posters
Presentations
Methods
Videos

Advanced Search
Use the fields below for a more refined search of the library
Author Year Title
Source Type

Through this library you can find an extensive list of British American Tobacco's peer-reviewed publications.

We have also included a selection of our recent posters, presentations, conference abstracts and scientific methods that are relevant to the content of this website and that have not typically been subject to external scientific peer-review.

[Back to top](#)

Transparency:

- 'Visitors Welcome' at GR&D
 - 2012: 34 groups, >300 visitors
 - Hosting external conferences

Ready for regulation?

2013: State of the art on
in vitro alternative methods
from an industrial point of view

In Vitro Testing Industrial Platform
IVTIP Spring 2013 meeting

May 14th–16th 2013
Southampton, UK

The meeting is kindly hosted by the IVTIP member company British American Tobacco (www.bat-science.com)



4th April 2012

Venue: Group Research & Development, British American Tobacco, Southampton

Registration by email to:
Peter_Branton@bat.com

Registration form at:
<http://www.britishcarbon.org>



**The
British Carbon Group**

2nd ANNOUNCEMENT

'Real World Applications of Carbons' is a one day meeting that aims to bring together scientists from Industry and Academia working in the field of carbon science. Carbon exists in many forms and has a range of diverse applications from personal protection to energy storage.

This meeting is provided free-of-charge - there will be **NO** registration fee and travel bursaries from BCG may be available to students.




Research Partners:

- Contract Research Organisations
- Academic Research Organisations
- Commercial partners
- CORESTA, multi-sector expert groups
- Future – Support for TCORS, NIH funded projects?



Governance / Conduct:

- Our research governance includes
 - Registration of clinical studies
 - Oversight of clinical studies by Ethics Committees
 - GXP (CRO's, and increasing internal standards)
 - Implementation of regulatory compliant QM & IT systems
- Support principle of disclosure of MRTPa data
- Use of Independent 3rd Party Research Organisations
 - Correct governance negates the need in general, however;
 - A consideration for specific research areas (e.g. vulnerable groups)





Summary:

- New generation of tobacco industry scientists
- Expertise: significant existing, growing in other areas
- Transparent approach keeps us in touch with mainstream scientific community
- Consistent with majority IOM's governance views
- With the correct governance in place, independent 3rd party approach not required for majority of research



Thank You!

www.bat-science.com

we welcome your comments